JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

Search

Danaher Corp

Ouvert

SecteurSoins de santé

200.49 0.26

Résumé

Variation du prix de l'action

24h

Actuel

Min

199.08

Max

200.67

Chiffres clés

By Trading Economics

Revenu

-399M

555M

Ventes

195M

5.9B

P/E

Moyenne du Secteur

41.835

34.393

BPA

1.8

Rendement du dividende

0.6

Marge bénéficiaire

9.35

Employés

61,000

EBITDA

-1B

760M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+19.21% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

0.60%

2.54%

Prochains Résultats

21 oct. 2025

Date du Prochain Dividende

24 oct. 2025

Date du Prochain Détachement de Dividende

26 sept. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

6.8B

141B

Ouverture précédente

200.23

Clôture précédente

200.49

Sentiment de l'Actualité

By Acuity

44%

56%

147 / 374 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Bullish Evidence

Danaher Corp Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

22 juil. 2025, 11:32 UTC

Résultats

Danaher Posts Lower 2Q Profit, Names Next CFO -- Update

22 juil. 2025, 10:42 UTC

Résultats

Danaher Posts Higher 2Q Sales, Lower Profit

22 avr. 2025, 10:34 UTC

Résultats

Danaher 1Q Results Decline But Top Estimates

5 févr. 2025, 12:54 UTC

Résultats

Johnson Controls Names Weidemanis CEO, Logs 1Q Income Growth

29 janv. 2025, 11:44 UTC

Résultats

Danaher 4Q Revenue Rises on Gains in Life Sciences, Biotech

22 juil. 2025, 10:03 UTC

Résultats

Danaher Had Seen 2025 Adjusted EPS $7.60-$7.75 >DHR

22 juil. 2025, 10:03 UTC

Résultats

Danaher Raises 2025 View To Adj EPS $7.70-Adj EPS $7.80 >DHR

22 juil. 2025, 10:02 UTC

Résultats

Danaher Still Sees 2025 Core Revenue Up About 3% >DHR

22 juil. 2025, 10:01 UTC

Résultats

Danaher Sees 3Q Core Revenue Up Low-Single Digits >DHR

22 juil. 2025, 10:00 UTC

Résultats

Danaher 2Q Operating Cash Flow $1.3B, Free Cash Flow $1.1B >DHR

22 juil. 2025, 10:00 UTC

Résultats

Danaher 2Q Net $555M >DHR

22 juil. 2025, 10:00 UTC

Résultats

Danaher 2Q Sales $5.9B >DHR

22 juil. 2025, 10:00 UTC

Résultats

Danaher 2Q Adj EPS $1.80 >DHR

22 juil. 2025, 10:00 UTC

Résultats

Danaher 2Q EPS 77c >DHR

22 juil. 2025, 09:34 UTC

Actions en Tendance

Stocks to Watch Tuesday: Coca-Cola, GM, AstraZeneca, NXP -- WSJ

14 juil. 2025, 16:12 UTC

Market Talk
Acquisitions, Fusions, Rachats

Waters Closer to Thermo Fisher, Danaher With Becton Dickinson Unit -- Market Talk

22 avr. 2025, 10:02 UTC

Résultats

Danaher Still Sees 2025 Adjusted Core Revenue Up About 3% >DHR

22 avr. 2025, 10:02 UTC

Résultats

Danaher Sees 2025 Adj EPS $7.60-Adj EPS $7.75 >DHR

22 avr. 2025, 10:02 UTC

Résultats

Danaher Sees 2Q Adjusted Core Revenue Up Low-Single Digits >DHR

22 avr. 2025, 10:01 UTC

Résultats

Danaher: Macro Backdrop Has Become More Dynamic Since Start of Year >DHR

22 avr. 2025, 10:01 UTC

Résultats

Danaher 1Q Adjusted Core Revenue Flat >DHR

22 avr. 2025, 10:00 UTC

Résultats

Danaher 1Q Operating Cash Flow $1.3B, Adjusted Free Cash Flow $1.1B >DHR

22 avr. 2025, 10:00 UTC

Résultats

Danaher 1Q Adj EPS $1.88 >DHR

22 avr. 2025, 10:00 UTC

Résultats

Danaher 1Q EPS $1.32 >DHR

22 avr. 2025, 10:00 UTC

Résultats

Danaher 1Q Sales $5.74B >DHR

22 avr. 2025, 10:00 UTC

Résultats

Danaher 1Q Net $954M >DHR

29 janv. 2025, 15:25 UTC

Market Talk
Résultats

Danaher's 2025 Sales Guidance Disappoints -- Market Talk

29 janv. 2025, 13:56 UTC

Actualités
Résultats

Danaher Had an Unusual Quarter. The Stock Is Down. -- Barrons.com

29 janv. 2025, 11:08 UTC

Résultats

Danaher Sees 2025 Bioprocessing Core Revenue Growth 6%-7% >DHR

29 janv. 2025, 11:07 UTC

Résultats

Danaher Sees 2025 Adjusted Operating Profit Margin About 28.5% >DHR

Comparaison

Variation de prix

Danaher Corp prévision

Objectif de Prix

By TipRanks

19.21% hausse

Prévisions sur 12 Mois

Moyen 238.13 USD  19.21%

Haut 275 USD

Bas 205 USD

Basé sur 17 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

17 ratings

14

Achat

3

Maintien

0

Vente

Score Technique

By Trading Central

189.8851 / 196.5Support & Résistance

Court Terme

Bullish Evidence

Moyen Terme

Weak Bullish Evidence

Long Terme

Neutral Evidence

Sentiment

By Acuity

147 / 374Classement par Soins de santé

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Danaher Corp

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company has a research collaboration with Stanford University's Department of Bioengineering for cancer drug development. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.